Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04594733 · ClinicalTrials.gov registry record · Phase 1
The Effect of Minocycline and N-acetylcysteine for the Treatment of Fibromyalgia
A Phase 1 study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT04594733: Completed Phase 1 study, sponsored by Medical University of South Carolina.
NCT04594733 is a Phase 1 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 14 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04594733, a Phase 1 study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
Evaluation of the effect of combinatorial treatment of fibromyalgia patients (standard of care + minocycline + N-acetylcysteine (NAC) relative to standard of care on subjective pain measurement Revised Fibromyalgia Impact Questionnaire (FIQR).
Primary Outcome
The FIQR (Revised Fibromyalgia Impact Questionnaire) is comprised of 21 questions spread across 3 domains: function, overall impact, symptoms, scored on an 11-point numeric rating scale. The questions are framed with the context of the past 7 days. The instructions ask the patient to rate the difficulty on a scale of 0-10 (0 = No difficulty, and 10 = Very difficult) which indicates how much difficulty they have experienced in doing the specified activity during the past 7 days. Each item is rate
Interventions
- DRUG minocycline (200 mg daily) and NAC (1200 mg daily) followed by placebo
- DRUG Placebo followed by minocycline (200 mg daily) and NAC (1200 mg daily)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2021-12-06 |
| Est. Completion | 2022-08-31 |
| Phase | Phase 1 |
What the finished NCT04594733 record still lists
NCT04594733 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 2 interventions - of which minocycline (200 mg daily) and NAC (1200 mg daily) followed by placebo is the first listed.
NCT04594733 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04594733 about?
NCT04594733 is a clinical study titled "The Effect of Minocycline and N-acetylcysteine for the Treatment of Fibromyalgia". Evaluation of the effect of combinatorial treatment of fibromyalgia patients (standard of care + minocycline + N-acetylcysteine (NAC) relative to standard of care on subjective pain measurement Revised Fibromyalgia Impact Questionnaire (FIQR).
What is the current status of trial NCT04594733?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2021-12-06. Estimated completion is 2022-08-31.
What interventions are being tested in trial NCT04594733?
The interventions under investigation include: minocycline (200 mg daily) and NAC (1200 mg daily) followed by placebo (DRUG), Placebo followed by minocycline (200 mg daily) and NAC (1200 mg daily) (DRUG).
Who is sponsoring clinical trial NCT04594733?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04594733's enrollment target sits among peer trials
14 1844th of 2000 higher than 154 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy